MRES.US Institute of Biomedical Research Corp
- Market cap
- USD 3.46M
- P/E
- -
- P/B
- 0.69x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is MRES.US undervalued?
Graham numberThe Graham number of Institute of Biomedical Research Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Institute of Biomedical Research Corp fundamental analysis
No fundamental analysis for Institute of Biomedical Research Corp yet.
Institute of Biomedical Research Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Institute of Biomedical Research Corp
Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental …
Full company profileInstitute of Biomedical Research Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Institute of Biomedical Research Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2013 | 2014 | 2015 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 522K | 1.13M | 1.41M | - | - | 29.4K | 45.1K | 49.5K | 27.7K | 100K |
| Gross Profit | - | 452K | 984K | 1.06M | - | - | 8.67K | 8.55K | 21.4K | -1.50K | -39.9K |
| Operating Income | -262K | 3.57K | 592K | 935K | -44.2K | -167K | -724K | -1.80M | -757K | -307K | -177K |
| EBITDA | -239K | - | - | - | -44.2K | -167K | -384K | 1.39M | -724K | -307K | -177K |
| Net Income | -273K | -29.0K | 524K | 565K | -44.2K | -167K | -433K | 1.33M | -633K | -2.46M | -74.3K |
| EPS | -0.05 | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 76.4K | 928K | 4.94M | 5.28M | - | - | 638K | 3.49M | 3.31M | 43.6K | 46.6K |
| Total Liabilities | 422K | 1.37M | 3.91M | 4.18M | - | - | 759K | 935K | 776K | 638K | 641K |
| Shareholders' Equity | -345K | -443K | 1.03M | 1.10M | - | - | -121K | 1.48M | 584K | -578K | -583K |
| Cash & Short-term Investments | - | 12.4K | 320K | 2.06M | - | - | 5.20K | 99.4K | 11.8K | 13.0K | 18.9K |
| Total Debt | 402K | - | - | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -232K | 12.4K | 320K | 2.06M | - | - | - | - | - | - | 8.93M |
| Capital Expenditure | 7.50K | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | 0.00 |
| Free Cash Flow | -239K | - | - | - | - | - | - | - | - | - | - |
| Ratios | |||||||||||
| ROE | - | - | 50.9% | 51.2% | - | - | - | 89.6% | -108.4% | - | - |
| ROA | -358.1% | -3.1% | 10.6% | 10.7% | - | - | -67.9% | 38.1% | -19.1% | -5,643.0% | -159.3% |
| Net Profit Margin | - | -5.6% | 46.4% | 40.1% | - | - | -1,472.0% | 2,950.3% | -1,278.6% | -8,882.8% | -74.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Institute of Biomedical Research Corp dividends
Institute of Biomedical Research Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 28, 2014.
Who owns Institute of Biomedical Research Corp
Ownership data of Institute of Biomedical Research Corp is not available yet.
Institute of Biomedical Research Corp company profile
- Company name
- Institute of Biomedical Research Corp
- Ticker
- MRES.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- Ljubljanska bb, Podgorica, Montenegro, 81000
- Phone
- 382 20 663 075
- Website
- mrescorp.com
About Institute of Biomedical Research Corp
Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.
Institute of Biomedical Research Corp management
3- Dr. Drasko D. Pekovic Ph.D.Founder, Chairman of the Board, CEO & President
- Mr. Victor LangeChief Executive Officer of M2MMA
- Mr. Teodor BurteaDirector & Member of Scientific Council